Review Fractional Tiers
Our Approach
GxP Regulatory Velocity

Fractional quality leadership for biopharma

We embed senior Quality Directors directly into your preclinical and clinical pipelines. Build audit-ready GxP architectures, defend IND submissions, and maintain regulatory momentum without full-time executive burn.

Inspection Records

Audit readiness in practice

100%

FDA & EMA inspection clearance across client clinical programs

45 Days

Average duration from baseline audit to complete QMS deployment

38+

IND and CTA regulatory dossiers successfully defended to date

Deployment Models

Senior quality architecture

Targeted GxP Gap Remediation

Embedded Fractional Head of Quality

Intensive four-week diagnostic sprints assessing vendor compliance, data governance standards, and documentation controls ahead of major regulatory milestones.

Dedicated senior leadership integrated into your executive cadence. We build 21 CFR Part 11 compliant quality management systems, supervise contract manufacturing organizations, and own formal inspection readiness from preclinical phase through Phase III clinical operations.

Mock Audits & Inspection Defense

Rigorous simulated regulatory evaluations testing trial master files, laboratory notebooks, and facility SOPs against stringent current FDA and EMA audit protocols.

Core Discipline

Quality is the structural velocity of clinical data

Regulatory compliance is not an eleventh-hour administrative barrier before an IND filing. When built correctly into daily research protocols, rigorous GxP infrastructure protects data integrity, preserves development runway, and accelerates commercial validation.

Initiate Consultation

Schedule a regulatory consultation

Discuss your upcoming trial milestones, vendor audits, or quality staffing requirements with a veteran biopharma quality director.